Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
|Videos|December 22, 2020
Manageable and In Control
Author(s)Susan J. Noonan, MD, MPH
Daily routine and structure will decrease a patient's stress and give them a sense of accomplishment.
Advertisement
Susan Noonan, MD, MPH, talks how small, broken down tasks and a system will help patients maintain their mental health.
Dr Noonan is a physician consultant and Certified Peer Specialist in the Department of Psychiatry at McLean Hospital and the Massachusetts General Hospital. She is the author of four books and a blog on managing depression, most recently
Advertisement
Related to this article
Single-dose DT120 ODT delivers rapid, sustained anxiety relief in phase 3 GAD trial, supporting FDA breakthrough path and NDA plans.
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Pramipexole was associated with improvement in anhedonia and apathy, and with increased physical activity in patients with mood disorders, in a placebo-controlled trial that measured both behavioral and neurophysiologic change.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Review the developments in GLP-1s in 2026.
Yale trio-genomics study links hair-pulling and skin-picking to inherited OCD risk scores and rare DNA variants, hinting at shared brain pathways.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Insights on the New Adult ADHD Guidelines: A Conversation With the President of APSARD
2
FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval
3
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
4
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
5